Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens Arístides Aguilar Betancourt, C.A. González Delgado, Z. Cinza Estévez, J. Cabrera Martínez, G. Véliz Ríos, S.R. Moreno Aureoles- Roselló, R. Alemán Zaldívar, M. Alonso Guzmán, N. Figueroa Baile, P.A. Días Reyes, L. Olivera Ruano, A. Correa Fernández, Y. Lobaina-Matos, A. Delahanty Fernández, A.I. Juvier Madrazo, M.I. Alonso Martínez, M. Lago Baños, N. Puble Alvarez, M. David Baldo, R.E. Soto Mestre, M.V. Pérez Pérez, M.E. Peña Martínez, D. Acosta Escobar, M.J. Cerna Guanche, L. Mila Cáceres, R. Sánchez Betancourt, E. Hardy Rando, G.E. Guillén Nieto, V.L. Muzio González, J.C. Aguilar Rubido International Journal of Infectious Diseases Volume 11, Issue 5, Pages 394-401 (September 2007) DOI: 10.1016/j.ijid.2006.09.010 Copyright © 2006 International Society for Infectious Diseases Terms and Conditions
Figure 1 Kinetics of the anti-HBsAg antibody response in healthy adults nasally immunized with HBcAg–HBsAg vaccine candidate. Vaccine schedule: 0, 7, 15, 30, and 60 days. Blood samples were collected from subjects at days 30, 60, and 90. Vertical arrows: nasal vaccine inoculations. International Journal of Infectious Diseases 2007 11, 394-401DOI: (10.1016/j.ijid.2006.09.010) Copyright © 2006 International Society for Infectious Diseases Terms and Conditions